Corrigendum to 'Understanding p53 functions through p53 antibodies'.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Ultrasound - based deep learning radiomics nomogram for noninvasive prediction of p53 mutation status in hepatocellular carcinoma: a variational autoencoder based development and validation study.Frontiers in oncology · 2026
   Article
2. TREM2 promotes the proliferation and invasion of renal cell carcinoma cells by inhibiting the P53 signaling pathway.Oncology letters · 2024
   Article
3. Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant.Journal of hematology & oncology · 2024
   Article
4. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.Blood · 2022
   Article

Corrections and comments

• Erratum for
  Understanding p53 functions through p53 antibodies.2019

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.